Imenor

Methotrexate, the active ingredient in Imenor, is an antimetabolite (folate antagonist) presented as a strength/form for oral use. It treats rheumatoid arthritis, psoriasis, psoriatic arthritis and certain cancers in adult patients.

GNH USA supplies Imenor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is employed in inflammatory and oncologic conditions that involve rapid cell proliferation.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: improves skin lesions and reduces scaling. Psoriatic arthritis: alleviates joint pain and skin symptoms. Certain cancers (e.g., leukemia, lymphoma): interferes with cancer cell growth.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or weakness. - Mouth sores or ulceration. - Decreased blood cell counts. - Elevated liver enzymes. - Skin rash or itching.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial lung disease. - Life‑threatening infections due to bone‑marrow suppression. - Acute kidney injury. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bone‑marrow failure (aplastic anemia).

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

Monitor liver function: perform regular hepatic enzyme tests. Assess renal function: adjust dose if creatinine clearance is reduced. Perform complete blood count monitoring: watch for cytopenias. Avoid in pregnancy: drug is teratogenic and contraindicated. Store at room temperature: keep in the original pack, protect from moisture and light.

Methotrexate interacts with several medicines that can increase toxicity or reduce efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Live vaccines: heightened risk of infection. - Proton pump inhibitors: may reduce absorption.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Azathioprine or other immunosuppressants: increased immunosuppression. - Alcohol: heightened liver toxicity.